These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 27077889)

  • 1. Endothelial to Mesenchymal Transition (EndoMT) in the Pathogenesis of Human Fibrotic Diseases.
    Piera-Velazquez S; Mendoza FA; Jimenez SA
    J Clin Med; 2016 Apr; 5(4):. PubMed ID: 27077889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of Systemic Sclerosis-associated pulmonary fibrosis and pulmonary arterial hypertension. Myth or reality?
    Jimenez SA; Piera-Velazquez S
    Matrix Biol; 2016 Apr; 51():26-36. PubMed ID: 26807760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Fibrotic Diseases: Current Challenges in Fibrosis Research.
    Rosenbloom J; Macarak E; Piera-Velazquez S; Jimenez SA
    Methods Mol Biol; 2017; 1627():1-23. PubMed ID: 28836191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TGF-β-Induced Endothelial-Mesenchymal Transition in Fibrotic Diseases.
    Pardali E; Sanchez-Duffhues G; Gomez-Puerto MC; Ten Dijke P
    Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29039786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders.
    Piera-Velazquez S; Li Z; Jimenez SA
    Am J Pathol; 2011 Sep; 179(3):1074-80. PubMed ID: 21763673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of endothelial to mesenchymal transition in the pathogenesis of the vascular alterations in systemic sclerosis.
    Jimenez SA
    ISRN Rheumatol; 2013 Sep; 2013():835948. PubMed ID: 24175099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myofibroblasts in proliferative diabetic retinopathy can originate from infiltrating fibrocytes and through endothelial-to-mesenchymal transition (EndoMT).
    Abu El-Asrar AM; De Hertogh G; van den Eynde K; Alam K; Van Raemdonck K; Opdenakker G; Van Damme J; Geboes K; Struyf S
    Exp Eye Res; 2015 Mar; 132():179-89. PubMed ID: 25637870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanisms of endothelial to mesenchymal cell transition (EndoMT) in experimentally induced fibrotic diseases.
    Piera-Velazquez S; Jimenez SA
    Fibrogenesis Tissue Repair; 2012; 5(Suppl 1):S7. PubMed ID: 23259736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis.
    Manetti M; Romano E; Rosa I; Guiducci S; Bellando-Randone S; De Paulis A; Ibba-Manneschi L; Matucci-Cerinic M
    Ann Rheum Dis; 2017 May; 76(5):924-934. PubMed ID: 28062404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies for anti-fibrotic therapies.
    Rosenbloom J; Mendoza FA; Jimenez SA
    Biochim Biophys Acta; 2013 Jul; 1832(7):1088-103. PubMed ID: 23266403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct contribution of epithelium to organ fibrosis: epithelial-mesenchymal transition.
    Guarino M; Tosoni A; Nebuloni M
    Hum Pathol; 2009 Oct; 40(10):1365-76. PubMed ID: 19695676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study.
    Corallo C; Cutolo M; Kahaleh B; Pecetti G; Montella A; Chirico C; Soldano S; Nuti R; Giordano N
    Arthritis Res Ther; 2016 Oct; 18(1):228. PubMed ID: 27716320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-fibrotic effects of synthetic TGF-β1 and Smad oligodeoxynucleotide on kidney fibrosis in vivo and in vitro through inhibition of both epithelial dedifferentiation and endothelial-mesenchymal transitions.
    Gwon MG; An HJ; Kim JY; Kim WH; Gu H; Kim HJ; Leem J; Jung HJ; Park KK
    FASEB J; 2020 Jan; 34(1):333-349. PubMed ID: 31914629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular and molecular mechanisms of fibrosis.
    Wynn TA
    J Pathol; 2008 Jan; 214(2):199-210. PubMed ID: 18161745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review: Endothelial-myofibroblast transition, a new player in diabetic renal fibrosis.
    Li J; Bertram JF
    Nephrology (Carlton); 2010 Aug; 15(5):507-12. PubMed ID: 20649869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular players in lung fibrosis.
    Lekkerkerker AN; Aarbiou J; van Es T; Janssen RA
    Curr Pharm Des; 2012; 18(27):4093-102. PubMed ID: 22630084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelial-to-mesenchymal transition: Pathogenesis and therapeutic targets for chronic pulmonary and vascular diseases.
    Lu X; Gong J; Dennery PA; Yao H
    Biochem Pharmacol; 2019 Oct; 168():100-107. PubMed ID: 31251941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the endothelial-to-mesenchymal transition in renal fibrosis of chronic kidney disease.
    He J; Xu Y; Koya D; Kanasaki K
    Clin Exp Nephrol; 2013 Aug; 17(4):488-97. PubMed ID: 23430391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrosis: Sirtuins at the checkpoints of myofibroblast differentiation and profibrotic activity.
    Zullo A; Mancini FP; Schleip R; Wearing S; Klingler W
    Wound Repair Regen; 2021 Jul; 29(4):650-666. PubMed ID: 34077595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The origin of renal fibroblasts/myofibroblasts and the signals that trigger fibrosis.
    Sun YB; Qu X; Caruana G; Li J
    Differentiation; 2016 Sep; 92(3):102-107. PubMed ID: 27262400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.